153 related articles for article (PubMed ID: 9665135)
1. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3.
Kurokawa M; Mitani K; Irie K; Matsuyama T; Takahashi T; Chiba S; Yazaki Y; Matsumoto K; Hirai H
Nature; 1998 Jul; 394(6688):92-6. PubMed ID: 9665135
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of leukemogenesis by AML1/EVI-1.
Mitani K
Oncogene; 2004 May; 23(24):4263-9. PubMed ID: 15156182
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic mechanisms of Evi-1 protein.
Hirai H; Izutsu K; Kurokawa M; Mitani K
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S35-40. PubMed ID: 11587364
[TBL] [Abstract][Full Text] [Related]
4. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription.
Zhang Y; Feng XH; Derynck R
Nature; 1998 Aug; 394(6696):909-13. PubMed ID: 9732876
[TBL] [Abstract][Full Text] [Related]
5. The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells.
Kurokawa M; Mitani K; Imai Y; Ogawa S; Yazaki Y; Hirai H
Blood; 1998 Dec; 92(11):4003-12. PubMed ID: 9834202
[TBL] [Abstract][Full Text] [Related]
6. Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP.
Nitta E; Izutsu K; Yamaguchi Y; Imai Y; Ogawa S; Chiba S; Kurokawa M; Hirai H
Oncogene; 2005 Sep; 24(40):6165-73. PubMed ID: 15897867
[TBL] [Abstract][Full Text] [Related]
7. Inability of transforming growth factor-beta to cause SnoN degradation leads to resistance to transforming growth factor-beta-induced growth arrest in esophageal cancer cells.
Edmiston JS; Yeudall WA; Chung TD; Lebman DA
Cancer Res; 2005 Jun; 65(11):4782-8. PubMed ID: 15930298
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4.
Kretschmer A; Moepert K; Dames S; Sternberger M; Kaufmann J; Klippel A
Oncogene; 2003 Oct; 22(43):6748-63. PubMed ID: 14555988
[TBL] [Abstract][Full Text] [Related]
9. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 1 inhibits transforming growth factor-beta signaling.
Seo T; Park J; Choe J
Cancer Res; 2005 Mar; 65(5):1738-47. PubMed ID: 15753369
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability.
Zhu S; Goldschmidt-Clermont PJ; Dong C
Circ Res; 2004 Mar; 94(5):617-25. PubMed ID: 14739161
[TBL] [Abstract][Full Text] [Related]
11. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis.
Imai Y; Kurokawa M; Izutsu K; Hangaishi A; Maki K; Ogawa S; Chiba S; Mitani K; Hirai H
Oncogene; 2001 Jan; 20(1):88-96. PubMed ID: 11244507
[TBL] [Abstract][Full Text] [Related]
12. Roles for lysine residues of the MH2 domain of Smad3 in transforming growth factor-beta signaling.
Imoto S; Sugiyama K; Sekine Y; Matsuda T
FEBS Lett; 2005 May; 579(13):2853-62. PubMed ID: 15907489
[TBL] [Abstract][Full Text] [Related]
13. Interferon-gamma suppresses transforming growth factor-beta-induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model.
Kuga H; Morisaki T; Nakamura K; Onishi H; Noshiro H; Uchiyama A; Tanaka M; Katano M
Oncogene; 2003 Oct; 22(49):7838-47. PubMed ID: 14586410
[TBL] [Abstract][Full Text] [Related]
14. Cited2 modulates TGF-beta-mediated upregulation of MMP9.
Chou YT; Wang H; Chen Y; Danielpour D; Yang YC
Oncogene; 2006 Sep; 25(40):5547-60. PubMed ID: 16619037
[TBL] [Abstract][Full Text] [Related]
15. Tenascin-C upregulation by transforming growth factor-beta in human dermal fibroblasts involves Smad3, Sp1, and Ets1.
Jinnin M; Ihn H; Asano Y; Yamane K; Trojanowska M; Tamaki K
Oncogene; 2004 Mar; 23(9):1656-67. PubMed ID: 15001984
[TBL] [Abstract][Full Text] [Related]
16. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.
Kurokawa M; Mitani K; Yamagata T; Takahashi T; Izutsu K; Ogawa S; Moriguchi T; Nishida E; Yazaki Y; Hirai H
EMBO J; 2000 Jun; 19(12):2958-68. PubMed ID: 10856240
[TBL] [Abstract][Full Text] [Related]
17. Repression of bone morphogenetic protein and activin-inducible transcription by Evi-1.
Alliston T; Ko TC; Cao Y; Liang YY; Feng XH; Chang C; Derynck R
J Biol Chem; 2005 Jun; 280(25):24227-37. PubMed ID: 15849193
[TBL] [Abstract][Full Text] [Related]
18. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation.
Bartholomew C; Kilbey A; Clark AM; Walker M
Oncogene; 1997 Feb; 14(5):569-77. PubMed ID: 9053855
[TBL] [Abstract][Full Text] [Related]
19. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling.
Izutsu K; Kurokawa M; Imai Y; Maki K; Mitani K; Hirai H
Blood; 2001 May; 97(9):2815-22. PubMed ID: 11313276
[TBL] [Abstract][Full Text] [Related]
20. Evi-1 ZF1 DNA binding activity and a second distinct transcriptional repressor region are both required for optimal transformation of Rat1 fibroblasts.
Kilbey A; Bartholomew C
Oncogene; 1998 Apr; 16(17):2287-91. PubMed ID: 9619838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
